A cephalosporin C acylase mutant with enhanced acid resistance and its application
By site-directed mutagenesis of Pseudomonas sp. P130 cephalosporin C acylase, an acid-resistant mutant was constructed, solving the problem of low catalytic activity of the enzyme under acidic conditions and realizing the industrial production of 7-ACA with high efficiency.
Patent Information
- Application Number
- CN202611074137.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing natural cephalosporin C acylases exhibit low catalytic activity and poor stability under acidic conditions, limiting the industrial application of one-step enzymatic production of 7-aminocephalosporanic acid.
By modifying the Pseudomonas sp. P130 cephalosporin C acylase using site-directed mutagenesis, mutants such as T197D, R269E, G574D, R638A, V682L, and I631E were constructed to improve its catalytic activity and stability under acidic conditions.
It significantly improves the catalytic activity and substrate conversion efficiency of the enzyme, providing a highly efficient and economical biocatalyst and a new industrial solution for one-step enzymatic production of 7-ACA.
Smart Images

Figure FT_1 
Figure FT_2
Abstract
Description
Technical Field
[0001] This study belongs to the field of biocatalysis and protein engineering, and involves a cephalosporin C acylase mutant with enhanced acid resistance and its applications. Background Technology
[0002] 7-Aminocephalosporanic acid (7-ACA) is an important intermediate in the synthesis of cephalosporin antibiotics and has significant applications in the pharmaceutical industry. Traditional production methods mainly involve the chemical lysis of cephalosporin C (CPC) to prepare 7-ACA, but this method suffers from problems such as complex processes, severe pollution, and high energy consumption. Therefore, enzymatic production has gradually become a research hotspot.
[0003] Currently, enzymatic production mainly includes two-step and one-step enzymatic methods. The two-step enzymatic method first utilizes D-amino acid oxidase to catalyze the generation of an intermediate from CPC, and then uses GL-7-ACA acylase to generate 7-ACA. Although this process is relatively mature, it suffers from problems such as numerous byproducts, complex procedures, and high production costs.
[0004] The one-step enzymatic method utilizes cephalosporin C acylase to directly catalyze the production of 7-ACA from CPC. It has advantages such as short process, less pollution, and low cost, and is considered to be a more promising production route.
[0005] Currently discovered CPC acylases mainly originate from a few Pseudomonas strains, such as Pseudomonas sp. SE83, Pseudomonas diminuta N176, and Pseudomonas sp. P130. However, the natural enzymes have low catalytic efficiency for CPC, making it difficult to meet industrial needs.
[0006] Furthermore, existing CPC acylases typically catalyze under alkaline conditions, while the substrate CPC and product 7-ACA exhibit poor stability at high pH levels. Acidic conditions are more conducive to substrate and product stability, but the enzymes exhibit low activity and poor stability at low pH environments, severely limiting the industrial application of one-step enzymatic methods.
[0007] Currently, the publicly available CPC acylases are mainly derived from a few microbial strains, such as Pseudomonas sp. SE83, Pseudomonas diminuta N176, and Pseudomonas sp. P130. Although these enzymes can catalyze the production of 7-ACA from CPC, they generally perform better under alkaline conditions, with a significant decrease in enzyme activity under acidic conditions. Furthermore, the substrate CPC and the product 7-ACA exhibit poor stability under alkaline conditions, severely limiting the industrial application of one-step enzymatic methods.
[0008] Therefore, developing a cephalosporin C acylase that maintains high activity and stability under acidic conditions and improving its catalytic efficiency for CPC is of great research significance and industrial application value. Summary of the Invention
[0009] The purpose of this invention is to overcome the shortcomings of existing one-step enzymatic production technology of 7-aminocephalosporanic acid (7-ACA), and to solve the problems of low catalytic activity, poor stability, and low conversion efficiency of cephalosporin C (CPC) under acidic conditions of natural cephalosporin C acylase. This invention provides a novel CPC acylase with stronger acid resistance and higher catalytic activity to meet the industrial demand for efficient, economical, and green one-step enzymatic production of 7-ACA.
[0010] First, this invention focuses on cephalosporin C acylase from Pseudomonas sp. P130, obtaining its amino acid sequence via NCBI, and then combining it with... UniProt The database structure information is analyzed.
[0011] Based on this, the present invention screens key amino acid sites that affect the acid resistance of enzymes through amino acid sequence alignment, protein secondary structure analysis, tertiary structure analysis, molecular docking and molecular dynamics simulation.
[0012] Furthermore, structural analysis revealed that sites such as T197, R269, G574, R638, V682, and I631 have a significant impact on the stability of enzyme molecules in acidic environments. Therefore, single-point mutants and their combined mutants, namely T197D, R269E, G574D, R638A, V682L, and I631E, will be constructed.
[0013] This invention uses site-directed mutagenesis to construct mutant genes T197D, R269E, G574D, R638A, V682L, and I631E, and expresses them through PCR amplification, plasmid construction, and introduction into E. coli host cells.
[0014] The obtained mutant enzyme was isolated and purified, and its enzyme activity and acid stability under different pH conditions were determined.
[0015] The results showed that the optimal mutant T197D, obtained by site-directed mutagenesis of the wild-type enzyme, exhibited higher catalytic activity and acid stability under acidic conditions and significantly improved the conversion efficiency of CPC to 7-ACA.
[0016] Therefore, the present invention provides a cephalosporin C acylase mutant whose amino acid sequence, corresponding to the amino acid sequence shown in SEQ ID NO:1, contains one or more of the following amino acid substitution mutations: T197D, R269E, G574D, R638A, V682L, I631E.
[0017] Specifically, its amino acid sequence, corresponding to the amino acid sequence shown in SEQ ID NO:1, contains one or more of the following amino acid substitution mutations: T197D, R269E, G574D, R638A, V682L, I631E, T197D+V682L, T197D+I631E, T197D+R269E, T197D+G574D, I631E+R638A, T197D+V682L+R638A, or T197D+I631E+R269E.
[0018] The present invention provides a polynucleotide encoding the cephalosporin C acylase C mutant.
[0019] Specifically, the coding polynucleotide sequence has a codon mutation compared to SEQ ID NO:2, thereby introducing a coding sequence of any one or a combination of T197D, R269E, G574D, R638A, V682L, and I631E.
[0020] The present invention provides a recombinant vector comprising the aforementioned encoding polynucleotide.
[0021] The present invention also provides a recombinant host cell containing the recombinant vector described above.
[0022] The present invention further provides the application of the cephalosporin C acylase mutant, the encoded polynucleotide, the recombinant vector, or the recombinant host cell in the catalytic production of 7-aminocephalosporanic acid.
[0023] A method for catalytically producing 7-aminocephalosporanic acid, using cephalosporin C as a substrate and employing the cephalosporin C acylase mutant as described in claim 1 or 2 as a catalytic enzyme to catalyze the production of 7-aminocephalosporanic acid.
[0024] Specifically, the reaction system uses 50-200mM CPC sodium salt as substrate, the buffer solution is Na2HPO4-KH2PO4 with pH 4-11, the reaction temperature is 30-40℃, and the amount of enzyme added to the reaction system is 0.01-1mg / mL.
[0025] More specifically, the reaction system uses 80-120mM CPC sodium salt as substrate, the buffer solution is Na2HPO4-KH2PO4 with pH 5-10, the reaction temperature is 36-38℃, and the amount of enzyme added to the reaction system is 0.05-0.15mg / mL. Furthermore, after the reaction is completed, the reaction is terminated by adding a mixture of ammonium acetate buffer and methanol in a ratio of 3:1.
[0026] In addition, it includes specific steps for separation and purification using Ni-NTA affinity chromatography.
[0027] The technical solution of this invention yielded several acid-enhanced cephalosporin C acylase mutants, including single-point mutants such as T197D, R269E, G574D, R638A, V682L, and I631E, as well as combined mutants such as T197D+V682L, T197D+I631E, T197D+R269E, T197D+G574D, I631E+R638A, T197D+V682L+R638A, and T197D+I631E+R269E. All of these mutants can catalyze the conversion of CPC to 7-ACA and exhibit superior catalytic performance compared to the wild-type enzyme under low pH conditions. Among them, T197D is the preferred single-point mutation site, which significantly improves both catalytic activity and acid stability. Further combined mutants constructed based on this exhibit superior catalytic performance, especially the T197D+I631E+R269E combined mutant, which has the highest specific enzyme activity, indicating a synergistic effect among multiple beneficial mutation sites. The series of mutants obtained in this invention significantly improve the catalytic activity, stability, and CPC conversion efficiency of CPC acylase under acidic conditions, providing a new and highly efficient biocatalyst for the one-step enzymatic industrial production of 7-ACA, and offering a new technical approach for the rational design and engineering modification of cephalosporin C acylase to improve acid resistance. Attached Figure Description
[0028] Figure 1 Liquid phase diagram and structural formula of enzyme-catalyzed CPC to 7-ACA.
[0029] Figure 2 The stability of wild-type and the optimal mutant T197D under acidic pH 6.5 conditions for 1 h, 2 h, 3 h, and 4 h of incubation. Detailed Implementation
[0030] Example 1: Screening of key mutation sites for cephalosporin C acylase
[0031] Currently reported acylases with CPC catalytic activity mainly originate from a few Pseudomonas strains. Among them, the cephalosporin C acylase derived from Pseudomonas sp. P130 exhibits good CPC catalytic activity and a high expression level, making it an important target for CPC acylase engineering modification research in recent years. However, the catalytic activity and stability of this enzyme under acidic conditions remain insufficient, limiting its application in the one-step enzymatic industrial production of 7-ACA. Therefore, this invention selects the cephalosporin C acylase derived from Pseudomonas sp. P130 (corresponding GenBank amino acid sequence accession number AAC34685.2) as the research object. The amino acid sequence of this acylase is as follows (SEQ ID No: 1):
[0032] Using cephalosporin C acylase from Pseudomonas sp. P130 as the research object, its nucleic acid sequence and amino acid sequence information were obtained from the NCBI database, and combined with... UniProt Protein structure information was obtained from databases. Multiple sequence alignment was performed using Clustal Omega to analyze conserved and variable regions among different CPC acylases, and non-conserved sites that may affect enzyme acid resistance were screened.
[0033] Based on PyMOL, we performed visualization analysis of the enzyme's three-dimensional structure, focusing on the catalytic center, substrate binding pocket, and protein surface charge distribution.
[0034] We further used AutoDock Vina to perform molecular docking between cephalosporin C (CPC) and the enzyme to analyze the substrate binding mode.
[0035] Based on the combined results of sequence analysis, structural analysis, molecular docking, and molecular dynamics, it was found that the T197, R269, G574, R638, V682, and I631 sites have a significant impact on the local structural stability under acidic conditions, and therefore they were identified as key modification sites.
[0036] Based on the combined results of sequence analysis, structural analysis, molecular docking, and molecular dynamics, it was found that the T197, R269, G574, R638, V682, and I631 sites have a significant impact on the local structural stability under acidic conditions, and therefore they were identified as key modification sites.
[0037] Example 2: Construction of single-site and combined mutants of T197D, R269E, G574D, R638A, V682L, and I631E
[0038] Using the wild-type cephalosporin C acylase gene as a template (Pseudomonas sp. P130), site-directed mutagenesis primers containing the T197D, R269E, G574D, R638A, V682L, and I631E mutation sites were designed.
[0039] The PCR amplification system is as follows (total reaction volume: 30 μL):
[0040] ;
[0041] The PCR reaction conditions were as follows: 98℃ pre-denaturation for 2 min; 98℃ denaturation for 10 s; 55-60℃ annealing for 15 s; 72℃ extension for 30 s; 30 cycles; 72℃ final extension for 2 min.
[0042] The PCR product was digested with Dpn I and transformed into Ecoli DH5α competent cells.
[0043] Positive clones were selected for sequencing verification, confirming the acquisition of mutant plasmids T197D, R269E, G574D, R638A, V682L, and I631E. Subsequently, combined mutants were constructed based on the single-point mutant plasmids.
[0044] Example 3 Expression and purification of cephalosporin C acylase mutant
[0045] Recombinant plasmids T197D, R269E, G574D, R638A, V682L, and I631E, along with combined mutant plasmids, with correct sequencing results were transformed into BL21(DE3) competent cells.
[0046] The transformed strain was inoculated into TB medium containing 50 μg / mL kanamycin and cultured at 37°C until OD600 = 0.6-1.0.
[0047] IPTG was added to a final concentration of 0.1 mmol / L to induce expression, and the cells were cultured at 25°C for 12-16 h.
[0048] After the culture was completed, the cells were collected by centrifugation at 4000 rpm for 15 min and resuspended in 50 mM Na2HPO4-KH2PO4 buffer (pH 8.0).
[0049] Cell disruption was performed using a high-pressure homogenizer: the disruption solution was centrifuged at 7500 rpm for 60 min, and the supernatant was used as the crude enzyme solution.
[0050] The target protein was further purified by Ni-NTA affinity chromatography. The steps are as follows:
[0051] a) Ni-NTA column pre-equilibration, with equilibration buffer consisting of 50 mM Na2HPO4-KH2PO4 and 30 mM imidazole (pH 8.0).
[0052] b) Load the sample at a flow rate of 1 mL / min to bind the His-tagged target protein to the packing material;
[0053] c) Wash the column bed with equilibration buffer containing 30 mM imidazole to remove non-specifically bound proteins;
[0054] d) Elute the target protein with elution buffer containing 500 mM imidazole (50 mM Na2HPO4-KH2PO4 pH 8.0);
[0055] e) Collect the elution fraction and dialyze it (molecular weight cutoff 10 kDa) in 50 mM Na2HPO4-KH2PO4 buffer (pH 8.0) to remove residual imidazole.
[0056] Example 4 Enzymatic Properties Analysis of Cephalosporin C Acylase Mutant
[0057] The enzyme activities of the wild-type enzyme and the mutant were measured at pH 6; acid stability was assessed by incubating in an acidic buffer system (pH 6.5) for 1, 2, 3, and 4 hours, and then measuring the enzyme activity (results are shown in the figure). Figure 2 (As shown).
[0058] Buffer system: Phosphate buffer (100mM, pH 4.0-11.0)
[0059] The total volume of the reaction system was 1 mL, including: 100 mM buffer, 100 mM CPC substrate; and 0.1 mg / mL purified enzyme solution.
[0060] The reaction was carried out at 37°C for 1 min.
[0061] After the reaction was complete, ammonium acetate buffer and methanol were added to terminate the reaction. The sample was then filtered through a 0.22 μm filter before analysis.
[0062] The content of 7-ACA in the product was determined by HPLC. Figure 1 As shown, a standard curve was plotted using CPC and 7-ACA standards, and the product yield was calculated from the peak area. Enzyme activity is defined as the amount of enzyme required to catalyze the conversion of 1 μmol of substrate into product per minute under specified conditions; specific enzyme activity is the enzyme activity per unit mass of enzyme protein.
[0063] Experimental results showed that the enzyme activity of the mutant was higher than that of the wild type at low pH. Among them, the optimal single-point mutant T197D had an enzyme activity 1.8 times higher than that of the wild type under acidic conditions (pH 6) (Table 1).
[0064] Based on the T197D mutation, the enzyme was mutated and expressed according to Examples 2 and 3, and the enzyme activity was measured to obtain the specific enzyme activity shown in Table 1 below.
[0065] Table 1 Enzyme activity of mutants under acidic conditions (pH 6)
[0066] ;
[0067] In summary, this invention, through targeted modification of key sites of cephalosporin C acylase, successfully obtained: double mutations of T197D and V682L, double mutations of T197D and I631E, double mutations of T197D and R269E, double mutations of T197D and G574D, double mutations of I631E and R638A, as well as two triple mutation combinations: T197D+V682L+R638A and T197D+I631E+R269E. These mutants can efficiently catalyze the production of 7-ACA from CPC and significantly improve the enzyme's catalytic activity, stability, and substrate conversion efficiency under acidic conditions. This invention provides a new and highly efficient biocatalyst for the one-step enzymatic industrial production of 7-ACA and offers new research ideas for the rational modification of cephalosporin C acylase.
Claims
1. A cephalosporin C acylase mutant, characterized in that, Its amino acid sequence, corresponding to the amino acid sequence shown in SEQ ID NO:1, contains one or more of the following amino acid substitution mutations: T197D, R269E, G574D, R638A, V682L, I631E.
2. The cephalosporin C acylase mutant according to claim 1, characterized in that, Its amino acid sequence, corresponding to the amino acid sequence shown in SEQ ID NO:1, contains one or more of the following amino acid substitution mutations: T197D, R269E, G574D, R638A, V682L, I631E, T197D+V682L, T197D+I631E, T197D+R269E, T197D+G574D, I631E+R638A, T197D+V682L+R638A, or T197D+I631E+R269E.
3. The polynucleotide encoded by the cephalosporin C acylase C mutant as described in claim 1 or 2.
4. The polynucleotide encoding according to claim 3, characterized in that, The encoded polynucleotide sequence has a codon mutation compared to SEQ ID NO:2, thereby introducing a coding sequence of any one or a combination of T197D, R269E, G574D, R638A, V682L, and I631E.
5. A recombinant vector, characterized in that, It contains the encoded polynucleotide as described in claim 3 or 4.
6. A recombinant host cell, characterized in that, It contains the recombinant vector as described in claim 5.
7. The use of the cephalosporin C acylase mutant of claim 1 or 2, the encoding polynucleotide of claim 3 or 4, the recombinant vector of claim 5, or the recombinant host cell of claim 6 in the catalytic production of 7-aminocephalosporanic acid.
8. A method for catalytic production of 7-aminocephalosporanic acid, characterized in that, Using cephalosporin C as a substrate, and employing the cephalosporin C acylase mutant as described in claim 1 or 2 as a catalytic enzyme, 7-aminocephalosporanic acid is catalyzed.
9. The method according to claim 8, characterized in that, The reaction system uses 50-200mM CPC sodium salt as substrate, the buffer solution is Na2HPO4-KH2PO4 with pH 4-11, the reaction temperature is 30-40℃, and the amount of enzyme added to the reaction system is 0.01-1mg / mL.
10. The method according to claim 9, characterized in that, The reaction system uses 80-120mM CPC sodium salt as substrate, the buffer solution is Na2HPO4-KH2PO4 with pH 5-10, the reaction temperature is 36-38℃, and the amount of enzyme added to the reaction system is 0.05-0.15mg / mL.
